Find, compare & contact
Thymosin beta-4
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Thymosin beta-4 API 77642-24-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Thymosin beta-4. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Thymosin beta-4
- Synonyms:
- Thymosin beta 4
- Cas Number:
- 77642-24-1
- DrugBank number:
- DB12003
- Unique Ingredient Identifier:
- 549LM7U24W
General Description:
Thymosin beta-4, identified by CAS number 77642-24-1, is a notable compound with significant therapeutic applications. Thymosin Beta 4 has been investigated for the treatment of STEMI, Dry Eye, Diabetes, Pressure Ulcers, and Dry Eye Syndrome, among others.
Classification:
Thymosin beta-4 belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Categories:
Thymosin beta-4 is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Microfilament Proteins, Peptide Hormones, Peptides, Proteins, Thymus Hormones. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Thymosin beta-4 is a type of Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
